Lantern Pharma annual r&d spending
2020
2021
2022
2023
2024
2025
Lantern Pharma R&D Spending Growth & History (LTRN)
Lantern Pharma's r&d spending was $11.5M for fiscal 2025.
View full Lantern Pharma company overviewLantern Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.5M | −$4.6M | −28.60% |
| 2024 | 2024-12-31 | $16.1M | $4.2M | +35.57% |
| 2023 | 2023-12-31 | $11.9M | $3.3M | +38.26% |
| 2022 | 2022-12-31 | $8.6M | $1.0M | +13.64% |
| 2021 | 2021-12-31 | $7.6M | $5.3M | +237.49% |
| 2020 | 2020-12-31 | $2.2M | — | — |
Lantern Pharma quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | −$1.3M | −41.64% |
| Q1 2026 | 2026-03-31 | $1.7M | −$1.5M | −47.15% |
| Q4 2025 | 2025-12-31 | $2.7M | −$1.5M | −35.71% |
| Q3 2025 | 2025-09-30 | $2.4M | −$1.3M | −34.43% |
| Q2 2025 | 2025-06-30 | $3.1M | −$820,358 | −21.10% |
| Q1 2025 | 2025-03-31 | $3.3M | −$986,831 | −23.22% |
| Q4 2024 | 2024-12-31 | $4.3M | $696,264 | +19.49% |
| Q3 2024 | 2024-09-30 | $3.7M | $1.5M | +68.18% |
| Q2 2024 | 2024-06-30 | $3.9M | $330,520 | +9.29% |
| Q1 2024 | 2024-03-31 | $4.3M | $1.7M | +66.51% |
| Q4 2023 | 2023-12-31 | $3.6M | $1.3M | +58.70% |
| Q3 2023 | 2023-09-30 | $2.2M | $1.5M | +214.67% |
| Q2 2023 | 2023-06-30 | $3.6M | $569,394 | +19.05% |
| Q1 2023 | 2023-03-31 | $2.6M | −$107,290 | −4.03% |
| Q4 2022 | 2022-12-31 | $2.3M | $89,338 | +4.13% |
| Q3 2022 | 2022-09-30 | $702,296 | −$2.3M | −76.31% |
| Q2 2022 | 2022-06-30 | $3.0M | $1.8M | +156.58% |
| Q1 2022 | 2022-03-31 | $2.7M | $1.4M | +107.99% |
| Q4 2021 | 2021-12-31 | $2.2M | $813,931 | +60.37% |
| Q3 2021 | 2021-09-30 | $3.0M | $2.4M | +393.43% |
| Q2 2021 | 2021-06-30 | $1.2M | $1.0M | +641.86% |
| Q1 2021 | 2021-03-31 | $1.3M | $1.1M | +832.90% |
| Q4 2020 | 2020-12-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $600,769 | — | — |
| Q2 2020 | 2020-06-30 | $157,023 | — | — |
| Q1 2020 | 2020-03-31 | $137,104 | — | — |
Lantern Pharma r&d spending trends
Over the last five fiscal years, Lantern Pharma's r&d spending increased from $2.2M to $11.5M, a change of $9.3M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lantern Pharma source filings ↗